GLP-1RAs and tirzepatide may lower heart failure risk in obese but not non-obese patients with heart or kidney disease

A total of 18 randomized controlled trials involving 97,800 patients demonstrated that GLP-1 receptor agonists significantly reduced the risk of cardiovascular and renal complications.

• GLP-1 receptor agonists decreased the risk of the primary composite outcome by 12% (RR 0.88, 95% CI 0.84-0.91, P < 0.001).
• There was a 12% reduction in the risk of death from any cause (RR 0.88, 95% CI 0.84-0.92, P < 0.001).
• The risk of death from cardiovascular causes was also reduced by 12% (RR 0.88, 95% CI 0.83-0.93, P < 0.001).
• No statistically significant overall effect on hospitalization for heart failure was found (RR 0.92, 95% CI 0.78-1.08), but a potential benefit was noted in obese patients (P for interaction = 0.02).
• GLP-1 receptor agonists had a lower incidence of serious adverse events (RR 0.93, 95% CI 0.89-0.99, P = 0.01) and cardiac adverse events (RR 0.90, 95% CI 0.85-0.96, P < 0.01) compared to placebo.

Simplified